Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Licenses SNaPIT Genotyping Technology from HiberGen

NEW YORK, July 9 - Sequenom has agreed to exclusively license HiberGen's SNaPIT genotyping technology for use with its MassArray mass spectrometry platform, the companies said Monday.

The license will allow San Diego-based Sequenom to develop and commercialize reagents and software for the MassArray system using HiberGen's technology. In return, Sequenom will pay HiberGen a license fee and royalties from sales of any SNaPIT-related products that Sequenom develops.

HiberGen, a population genomics and genotyping business based in Dublin, Ireland, will continue to use its SNaPIT technology to identify genetic markers associated with disease. The company also hopes to find other partners to license the SNaPIT technology for additional applications.

"Sequenom's reputation as a leader in SNP analysis, together with its strong links with academic and research centers make them an ideal partner for HiberGen as we pursue our strategy of out-licensing SNaPIT for use on a variety of detection platforms," Maurice Treacy, Chief Executive of HiberGen, said in a statement.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.